The practical question most people arrive with is simple to say and surprisingly hard to answer: the question of what to expect during your first ketamine infusion looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
For anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. Patients researching the United States providers run into this constantly. Read against the the United States market, the phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. Using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. Response, where it occurs, is frequently not permanent, and many people move onto maintenance sessions spaced every two to six weeks. It is the first thing to establish about any the United States programme.
None of the the United States detail on this page makes sense without the clinical context behind it. Preparation shapes the experience more than most people expect. Clinics typically ask patients to avoid solid food for several hours beforehand, largely because of nausea, and to arrange a ride home, because driving is off the table for the remainder of the day. Beyond the logistics, the psychological preparation matters: going in with a settled expectation that the dissociative period is temporary, expected and monitored tends to make it far less alarming than encountering it cold. People who have discussed in advance what they will do if they feel frightened, and who know that the infusion can be slowed or stopped, generally describe a calmer experience than those who have not.
Making the decision with the information available
Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. The subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. It is worth carrying that into every conversation with a the United States provider. Approval for esketamine extends to depressive symptoms in adults with major depressive disorder and acute suicidal ideation, a narrow and specific indication rather than a general one. Said another way, what people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit. That holds in the United States as it does everywhere: coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment.
Set aside the United States for a moment, because the general position comes first. A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
The underlying facts, stated once and clearly
For anyone weighing options in the United States, the useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. Advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. A standard induction runs to six sessions across two to three weeks, a figure inherited from early trial protocols rather than settled by comparative research. The the United States listings on this page are organised so that this is checkable rather than assumed.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. The evidence base deserves an honest summary rather than either dismissal or enthusiasm. Multiple randomised controlled trials have found rapid reductions in depressive symptom scores following single and repeated subanaesthetic ketamine infusions, with effects often visible within hours to days rather than weeks, and a separate line of research has examined rapid reduction of suicidal ideation specifically. Those are real findings from real trials. The significant limitations are equally real: many studies are small, blinding is notoriously difficult because the dissociative effect is obvious to participants, follow-up periods are usually short, and the question of what happens over years of maintenance has not been answered. A reasonable reading is that this is a promising and genuinely useful option for a specific population, not a settled standard of care for everyone.
Why this question is harder than it should be
Someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. Anyone comparing the United States programmes will find this decisive: esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions. Randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require. Nothing about the United States changes that. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account.
None of the the United States detail on this page makes sense without the clinical context behind it. Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
What to do next
Preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming. In the United States the same rule applies: travel time belongs in the treatment plan rather than being treated as a detail to solve later. Applied to the United States, the point is this: the population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. Antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. That is as true in the United States as anywhere else in the country. Six infusions over roughly three weeks is the common induction pattern, though some programmes offer four and others extend to eight. Patients researching the United States providers run into this constantly.
Every the United States programme is operating inside the same clinical framework, which runs as follows. In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
How the pieces fit together in practice
Headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. It is the first thing to establish about any the United States programme. That holds in the United States as it does everywhere: ketamine acts on the glutamate system rather than the monoamine pathways targeted by conventional antidepressants, which is the likely reason its timeline differs so sharply. Distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal. It is worth carrying that into every conversation with a the United States provider. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically.
None of the the United States detail on this page makes sense without the clinical context behind it. There is a specific population for whom this conversation is most relevant, and it is narrower than the advertising implies. The trial evidence concentrates on adults with major depressive disorder who have not responded adequately to at least two antidepressant trials at appropriate doses and durations. If someone has never tried a first-line treatment, the reasonable clinical answer is usually to start there, because the evidence is stronger, the cost is lower and the risk profile is better understood. A clinic that agrees to treat anyone who asks, without reference to what has been tried, has replaced clinical judgement with a booking system.
Putting this to use
Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. The the United States listings on this page are organised so that this is checkable rather than assumed. The induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. Anyone comparing the United States programmes will find this decisive: a dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced. Applied to the United States, the point is this: where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. For anyone weighing options in the United States, resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting.
The point of laying all this out is not to argue for or against treatment. It is to make sure that whichever way the decision goes, it is made with the real numbers and the real caveats rather than the marketing version.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.